BNT162b2 vaccine

BIOLOGICAL7 trials

Sponsors

Hong Kong Sanatorium & Hospital, Montefiore Medical Center, Giselle Guerra, Sheba Medical Center, Vaxxinity, Inc.

Conditions

COVID-19COVID-19 PandemicCOVID-19 VaccinesCancerCovid-19 VaccineCovid19SARS-COV-2 Infection

Phase 2

Booster Dose Trial

TerminatedNCT05016622

Montefiore Medical CenterCancer

Start: 2021-08-10End: 2023-05-21Updated: 2024-07-31

Phase 3

COVID-19 3rd Dose Vaccine in Transplant Patients

TerminatedNCT05047640

Giselle GuerraCovid19

Start: 2021-09-14End: 2022-10-25Updated: 2024-06-04

Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine

Vaxxinity, Inc.COVID-19 Vaccines

Start: 2022-03-16End: 2023-09-30Updated: 2022-10-14

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

Active, not recruitingNCT07300839

BioNTech SECOVID-19, SARS-COV-2 Infection

Start: 2025-12-10End: 2026-07-31Updated: 2026-04-13

Phase 4

Fourth BNT162b2 COVID-19 Vaccine Dose

Sheba Medical CenterCOVID-19 Pandemic

Start: 2021-12-27End: 2024-06-26Target: 1000Updated: 2023-12-27

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age

RecruitingNCT07730450

BioNTech SECOVID-19 Vaccines

Start: 2026-07-23End: 2027-08-20Target: 200Updated: 2026-08-07

Unknown Phase

Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong

CompletedNCT04898946

Hong Kong Sanatorium & HospitalCovid-19 Vaccine

Start: 2021-03-07End: 2021-12-31Updated: 2024-02-28

Related Papers

Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial.

2025-07-211 citations

Post hoc analysis: 6 Months immunogenicity after third dose of BNT162b2 vs JNJ-78,436,735 after two doses of BNT162b2 vaccine in solid organ transplant recipients.

2025-01-09

Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses

PLoS Pathogens2023-04-2036 citations

A Pilot Single-Blinded, Randomized, Controlled Trial Comparing BNT162b2 vs. JNJ-78436735 Vaccine as the Third Dose After Two Doses of BNT162b2 Vaccine in Solid Organ Transplant Recipients

Transplant International2023-04-056 citations

Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial

eLife2023-03-1432 citations

Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up.

2022-12-1322 citations